Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT06525766

Recruiting

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Metastatic Breast Cancer | Anatomic Stage IV Breast Cancer AJCC v8 | Estrogen-receptor-positive Breast Cancer | Metastatic HER2-Negative Breast Carcinoma
NCT06145399

Withdrawn

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Metastatic Breast Carcinoma | Female Breast Cancer
NCT07503496

Recruiting

Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy

Breast Cancer Stage III | Breast Cancer Stages I | Breast Cancer Stages II
NCT07367178

Not yet recruiting

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer (SATROPIN)

Breast Cancer | Advanced Triple-Negative Breast Cancer | Advanced HR+/HER2- Breast Cancer
NCT06787339

Not yet recruiting

Capecitabine in Low Risk Triple Negative Breast Cancer (Calorite)

Breast Cancer
NCT06869629

Not yet recruiting

Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer (SENOMAC-ULTRA)

Breast Surgery | Breast Cancer | Breast Carcinoma
NCT06721065

Recruiting

A Study of Language Interpretation Solutions for People With Breast Cancer

Breast Cancer | Breast Cancer Stage II | Breast Cancer Stage III
NCT06700382

Recruiting

Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC (NeoTNBCX)

Triple Negative Breast Cancer
NCT06508216

Recruiting

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer (COMPASS-TNBC)

Breast Cancer
NCT06446882

Recruiting

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer (DEFINITIVE)

HER2-positive Breast Cancer | Early-stage Breast Cancer
NCT06435351

Recruiting

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Breast Cancer | Triple Negative Breast Cancer
NCT06401005

Recruiting

SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

Breast Cancer
NCT06240195

Recruiting

Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study (BIO-PROSA)

Breast Cancer
NCT06182306

Recruiting

Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET) (PEAR-MET)

Breast Cancer | Triple Negative Breast Cancer
NCT05989828

Recruiting

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT05916755

Recruiting

Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform (PORTRAIT)

Triple Negative Breast Cancer
NCT05909332

Recruiting

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Breast Cancer | Triple Negative Breast Cancer
NCT05860621

Recruiting

Promoting Physical Activity in Breast Cancer Survivors on Aromatase Inhibitors (PAC-WOMAN)

Breast Cancer Female | Hormone-receptor-positive Breast Cancer
NCT05827081

Recruiting

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (Adjuvant WIDER)

Early Breast Cancer
NCT05769491

Not yet recruiting

Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials

Breast Cancer | Triple Negative Breast Cancer
NCT05681728

Recruiting

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Breast Cancer
NCT04861077

Recruiting

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

Triple Negative Breast Cancer
NCT04722978

Recruiting

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer
NCT04452370

Recruiting

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Triple Negative Breast Cancer
NCT04437160

Recruiting

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Triple Negative Breast Cancer
NCT04427293

Recruiting

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT04137653

Recruiting

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Breast Cancer
NCT03920488

Recruiting

Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer (PERSONA)

Triple Negative Breast Cancer
NCT01785420

Recruiting

Pre Operative Trastuzumab in Operable Breast Cancer

HER2 Positive Breast Cancer | Carcinoma Breast Stage I
NCT05498896

Active, not recruiting

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC (BARBICAN)

Triple Negative Breast Cancer
NCT06604858

Active, not recruiting

Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer (TELESCOPE)

Breast Cancer | Triple Negative Breast Cancer
NCT00066443

Completed

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Breast Cancer
NCT03301350

Completed

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Breast Cancer | Triple Negative Breast Cancer
NCT04852926

Completed

Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital. (ENVIE)

Breast Cancer | Breast Neoplasms | Breast Carcinoma | Breast Tumor
NCT03901469

Terminated

A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT03515798

Active, not recruiting

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (PELICAN)

Inflammatory Breast Cancer
NCT05435352

Terminated

Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment (PEAR-TNBC)

Triple Negative Breast Cancer | Triple Negative Breast Neoplasms
NCT05632848

Completed

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Triple Negative Breast Cancer
NCT06926335

Active, not recruiting

Oncological Safety of Oncoplastic Breast Surgery in Multicentric Breast Cancer

Breast Cancer | Breast Neoplasms | Safety of Breast Coservative Multicenteric Breast Cancer | Multicentric
NCT03168880

Active, not recruiting

A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT03800355

Completed

Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk

Breast Cancer, Male
NCT01901094

Active, not recruiting

Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy

Stage II Breast Cancer | Stage IIIA Breast Cancer
NCT03473691

Withdrawn

Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer (Breast50)

Triple Negative Breast Cancer
NCT06646263

Enrolling by invitation

Cellular Immune Responses in Triple-negative Breast Cancer - High Throughput Immunogenetic Studies

Triple Negative Breast Cancer
NCT05111067

Completed

Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity

Triple Negative Breast Cancer
NCT03498716

Terminated

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

Triple Negative Breast Cancer
NCT04613674

Completed

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer
NCT04461600

Terminated

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)

Triple Negative Breast Cancer
NCT04993625

Active, not recruiting

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study (ASLAN)

Breast Cancer
NCT02641847

Active, not recruiting

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Breast Cancer | Triple Negative Breast Cancer

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations